Table 1. Study characteristics.

Authors, year	Sorafenib treatment	TACE drug	Randomized	Blinding	Placebo controlled	Allocation concealed	Study Centers	Countries
Kudo et al., 2011	After 1 or 2 TACE sessions	epirubicin, cisplatin, doxorubicin, mitomycin	yes	Double	yes	no	4	1
Sansonno et al., 2012	30 days after TACE	Doxorubicin, mitomycin C	yes	Double	yes	yes	75	2
Hoffmann et al., 2015	Stopped 3 days before and resumed 3 days after TACE	Carboplatin	yes	Double	yes	no	85	13
Lencioni et al., 2016	3−7 days after first TACE	DEB-TACE, doxorubicin	yes	Double	yes	no	1	1